Moderna posted $1.2 billion in first quarter and expected to earn $6.20 /share on $4.41 billion in sales. The company already signed contracts worth $19.2 billion in product sales this year.
HOLD rating for $MRNA. With the buy zone in between $189.10-$198.56, the average high price target is still at $246 and an average low of $177.
Looking ahead to another milestone year for the company, it is currently sitting at a 98.05% increase YTD.
https://zyne.com/stock/MRNA
HOLD rating for $MRNA. With the buy zone in between $189.10-$198.56, the average high price target is still at $246 and an average low of $177.
Looking ahead to another milestone year for the company, it is currently sitting at a 98.05% increase YTD.
https://zyne.com/stock/MRNA
